The process for commercializing preclinically confirmed drugs currently has a success rate of only about 12%. |
|
abc biopply is a specialist for advanced solutions in preclinical disease models and drug discovery. The company has pioneered a unique portfolio of 3D tissue imaging and analysis assays enabling the easy and reliable generation of quantitative datasets from tissues and cells. Based on the proprietary 3D CoSeedis™ multi-organoid technology the company has boosted the relevance of in vitro testing to the ex vivo level. |
|
The related CRO services support pharmaceutical and biotech companies to improve the predictiveness of their preclinical models and to de-risk their drug discovery processes. |
This website uses cookies to ensure you get the best experience on our website. By using our services you agree that we use cookies. Privacy Policy